Eiko I Fukazawa1, Steven S Witkin2,3, Renata Robial1, João G Vinagre1, Edmund C Baracat1, Iara M Linhares1. 1. Department of Gynecology and Obstetrics, University of Sao Paulo Medical School, Sao Paulo, Brazil. 2. Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA. switkin@med.cornell.edu. 3. Institute of Tropical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil. switkin@med.cornell.edu.
Abstract
PURPOSE: More than 370 million women will experience recurrent vulvovaginal candidiasis (RVVC) during their lifetime. However, RVVC is often trivialized as clinically insignificant and not worthy of research funding. We evaluated the influence of RVVC on the quality of life in affected women. METHODS: The validated World Health Organization Quality of Life Abbreviated Assessment (WHOQOL-Bref) questionnaire was administered to 100 women with RVVC and to 101 epidemiologically matched women with no history of vulvovaginal candidiasis. RVVC was defined as at least four episodes of clinical and culture-positive vaginal candidiasis within a 1 year period. Data were analyzed by Chi square, Student t test and analysis of variance. Internal consistency of responses to questions was evaluated by Cronbach alpha. RESULTS: The Cronbach alpha coefficient was > 0.80 for responses to generalized questions and > 0.65 for answers to more specific questions, indicating substantial internal consistency. Perception of quality of life and satisfaction with their health was greatly reduced in the RVVC group (p < 0.001). Diminished responses to physical and psychological well-being were also reported by women with RVVC (p < 0.001). Various aspects of social relations including sexual activity were similarly reduced (p < 0.001) as were satisfaction with issues such as home environment, financial resources and employment (p < 0.001). CONCLUSION: RVVC affects multiple aspects of a woman's well-being. Women with this condition deserve serious attention from clinicians and research into susceptibility, prevention and treatment of this infection deserves much greater emphasis.
PURPOSE: More than 370 million women will experience recurrent vulvovaginal candidiasis (RVVC) during their lifetime. However, RVVC is often trivialized as clinically insignificant and not worthy of research funding. We evaluated the influence of RVVC on the quality of life in affected women. METHODS: The validated World Health Organization Quality of Life Abbreviated Assessment (WHOQOL-Bref) questionnaire was administered to 100 women with RVVC and to 101 epidemiologically matched women with no history of vulvovaginal candidiasis. RVVC was defined as at least four episodes of clinical and culture-positive vaginal candidiasis within a 1 year period. Data were analyzed by Chi square, Student t test and analysis of variance. Internal consistency of responses to questions was evaluated by Cronbach alpha. RESULTS: The Cronbach alpha coefficient was > 0.80 for responses to generalized questions and > 0.65 for answers to more specific questions, indicating substantial internal consistency. Perception of quality of life and satisfaction with their health was greatly reduced in the RVVC group (p < 0.001). Diminished responses to physical and psychological well-being were also reported by women with RVVC (p < 0.001). Various aspects of social relations including sexual activity were similarly reduced (p < 0.001) as were satisfaction with issues such as home environment, financial resources and employment (p < 0.001). CONCLUSION: RVVC affects multiple aspects of a woman's well-being. Women with this condition deserve serious attention from clinicians and research into susceptibility, prevention and treatment of this infection deserves much greater emphasis.
Entities:
Keywords:
Health questionnaire; Quality of life; Recurrent vulvovaginal candidiasis
Authors: Benjamin Kingsley Harley; David Neglo; Mike Okweesi Aggrey; Anthony Martin Quagraine; Emmanuel Orman; Jonathan Jato; Nana Ama Mireku-Gyimah; Cedric Dzidzor K Amengor; Theophilus Christian Fleischer Journal: Biomed Res Int Date: 2022-06-07 Impact factor: 3.246
Authors: Hannah R Eckert; Shunji Li; Mason A Shipley; Cooper R Roslund; Lance R Fredericks; Mark D Lee; Dina A Boikov; Emily A Kizer; Jack D Sobel; Paul A Rowley Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191
Authors: Leticia Martin-Cruz; Carmen Sevilla-Ortega; Cristina Benito-Villalvilla; Carmen M Diez-Rivero; Silvia Sanchez-Ramón; José Luis Subiza; Oscar Palomares Journal: Front Immunol Date: 2021-01-21 Impact factor: 7.561
Authors: Diletta Rosati; Mariolina Bruno; Martin Jaeger; Bart-Jan Kullberg; Frank van de Veerdonk; Mihai G Netea; Jaap Ten Oever Journal: J Infect Dis Date: 2022-05-16 Impact factor: 7.759
Authors: Moira Bradfield Strydom; Ramesh L Walpola; Sara McMillan; Sohil Khan; Robert S Ware; Evelin Tiralongo Journal: BMC Womens Health Date: 2022-09-19 Impact factor: 2.742
Authors: Gilbert Donders; István Oszkár Sziller; Jorma Paavonen; Phillip Hay; Francesco de Seta; Jean Marc Bohbot; Jan Kotarski; Jordi Antoni Vives; Bela Szabo; Ramona Cepuliené; Werner Mendling Journal: Front Cell Infect Microbiol Date: 2022-09-09 Impact factor: 6.073